Navigation Links
AtheroNova Completes Successful Pre-IND Meeting with FDA on AHRO-001
Date:10/26/2011

IRVINE, Calif., Oct. 26, 2011 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, today announced that it has completed its pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA). During the meeting, the FDA provided guidance on the development plan of AHRO-001, AtheroNova's lead patent-pending compound for the prevention and regression of atherosclerotic plaque. The goal of the pre-IND meeting was to obtain clarification on the nonclinical, clinical and chemical, manufacturing and control (CMC) requirements that need to be met in order to submit an acceptable IND.

"Our meeting with the FDA represents another important step in our clinical drug development plan. Our strategy to bring AHRO-001 into human clinical trials is now clear," said AtheroNova CEO Thomas Gardner. "Combined with our recent commitment from Maxwell Biotech Venture Fund to fund both Phase I and Phase II clinical trials and our licensing partnership with Maxwell Biotech Group, we are on track to commercialize novel therapies that can help millions of those suffering from cardiovascular disease."

About AHRO-001

AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AHRO-001 uses certain natural compounds to regress atherosclerotic plaque deposits through a process known as delipidization. Delipidization dissolves plaques in artery walls, which are then removed by natural body processes. AtheroNova plans to develop multiple applications for its patents-pending compounds that can be used in pharmaceutical-grade products for the treatment of atherosclerosis. Atherosclerosis and related pharmaceutical costs run more than $41 billion annually in the United States alone.  Market sectors potentially served by AHRO-001 include: Cardiovascular Disease, Stroke, Peripheral Artery Disease, Dementia and Alzheimer's and Erectile Dysfunction, all of which have been linked to atherosclerosis.

About AtheroNova

AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits. The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention. www.AtheroNova.com.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the Company's pipeline, milestones, future filings and trials, markets, mechanisms of action, licensing agreements and equity investment as well as the development of applications for AtheroNova's technology. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ORANGE COUNTY, Calif. , April 29, 2016 ... technology industry is projected to shift from systems ... can replace all types of modality CRT Medical ... set-up." Although there are a host of foreseeable ... a serious concern; will existing modalities have to ...
(Date:4/29/2016)... 2016 Interview ... Sanofi, leader mondial et diversifié ... pour le premier trimestre 2016. Le ... commente les résultats du premier trimestre ... le reste de l,année. ...
(Date:4/28/2016)... 2016   Click here for supplemental information ... DPLO), the nation,s largest independent specialty pharmacy, announced ... to acquire Valley Campus Pharmacy, Inc., doing business ... specialty pharmacy that provides individualized patient care, based ... In 2015, TNH generated approximately $400 million in ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... AvePoint, ... release of DocAve 6 Service Pack (SP) 7, the enterprise-class infrastructure ... 2016 and take advantage of the platform’s latest features – whether in an ...
(Date:5/3/2016)... ... May 03, 2016 , ... LunchSkins is changing the future of ... of single-use, throw away plastic baggies. The mission-driven bags give back to global leaders ... “The LunchSkins mission is all about reducing global plastic waste and we’ve ...
(Date:5/2/2016)... ... May 03, 2016 , ... ... FDA approved sSOIP telemedicine stethoscope software that enables the stethoscope stream to go ... PCP-SSP and works with RNK’s flagship PCP-USB stethoscope. , Remote auscultation involves two ...
(Date:5/2/2016)... ... ... As directed by its board of directors during its April 26 meeting, The ... nurse practitioners (CNP) to practice to the full scope of their license without the ... and 3,600 hours. , In addition, HAP supports CNPs who are licensed in another ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... educational website to help consumers better understand life insurance throughout various life stages. ... including an easy-to-use life insurance needs calculator and content specific to the times ...
Breaking Medicine News(10 mins):